Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Andrew Blumenfeld, Benjamin Frishberg, Jack Schim, et al.
Pain and Therapy (2021) Vol. 10, Iss. 2, pp. 809-826
Open Access | Times Cited: 78

Showing 26-50 of 78 citing articles:

Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
María Del Pilar Briceño-Casado, Manuel David Gil‐Sierra, Beatriz De-La-Calle-Riaguas
European Journal of Hospital Pharmacy (2021) Vol. 30, Iss. 4, pp. e19-e19
Open Access | Times Cited: 21
Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial
Debashish Chowdhury, Ankit Mundra, Debabrata Datta, et al.
Cephalalgia (2022) Vol. 42, Iss. 9, pp. 859-871
Closed Access | Times Cited: 13
A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine
Arathi Nandyala, Himanshu Suri, Carrie Dougherty, et al.
Clinical Neurology and Neurosurgery (2022) Vol. 215, pp. 107200-107200
Closed Access | Times Cited: 13
Chronic Migraine
Doris Kung, Gage Rodriguez, Randolph W. Evans
Neurologic Clinics (2022) Vol. 41, Iss. 1, pp. 141-159
Closed Access | Times Cited: 13
Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study
Claudia Altamura, Nicoletta Brunelli, Giovanna Viticchi, et al.
Toxins (2023) Vol. 15, Iss. 4, pp. 284-284
Open Access | Times Cited: 7
Treatment satisfaction with calcitonin gene‐related peptide monoclonal antibodies as a new patient‐reported outcome measure: A real‐life experience in migraine
A. López-Bravo, Antonio Oliveros‐Cid, Laura Sevillano‐Orte
Acta Neurologica Scandinavica (2022) Vol. 145, Iss. 6, pp. 669-675
Open Access | Times Cited: 12
Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study
Adrián Viudez‐Martínez, Angela Pascual‐Carrasco, Isabel Beltrán‐Blasco, et al.
Journal of Clinical Pharmacy and Therapeutics (2022) Vol. 47, Iss. 6, pp. 814-823
Open Access | Times Cited: 12
The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine
Simona Guerzoni, Carlo Baraldi, Luca Pani
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5687-5695
Closed Access | Times Cited: 12
Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions
Loredana Raciti, Gianfranco Raciti, David Militi, et al.
Journal of Integrative Neuroscience (2022) Vol. 21, Iss. 5
Open Access | Times Cited: 12
Comparative effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan
Yen‐Feng Wang, Fu‐Chi Yang, Lu‐An Chen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 9
Open Access | Times Cited: 2
Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA
Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 879-879
Open Access | Times Cited: 2
Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis
Ioana Medrea, Paul E. Cooper, M. J. S. Langman, et al.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024), pp. 1-23
Open Access | Times Cited: 2
OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation
Fan Cheng, Fayyaz Ahmed
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 11, pp. 1275-1289
Open Access | Times Cited: 13
Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
(2022)
Open Access | Times Cited: 9
Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
Shane Root, Kevin Ahn, Jack F. Kirsch, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 391-401
Open Access | Times Cited: 5
CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
Yen‐Feng Wang, Shuu‐Jiun Wang
Current Pain and Headache Reports (2022) Vol. 26, Iss. 7, pp. 543-554
Closed Access | Times Cited: 8
Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age
Laura Papetti, Ilaria Frattale, Fabiana Ursitti, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1802-1802
Open Access | Times Cited: 4
Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry
Vı́ctor Obach, Fernando Velasco, Rocío Álvarez Escudero, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study
Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, et al.
Cephalalgia Reports (2024) Vol. 7
Open Access | Times Cited: 1
Post-traumatic headache: Pathophysiology and management - A review
Andrew Blumenfeld, Jennifer McVige, Kerry Knievel
Journal of Concussion (2022) Vol. 6
Open Access | Times Cited: 7
Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
George R. Nissan, Richard D. Kim, Joshua M. Cohen, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4359-4359
Open Access | Times Cited: 7
Comparative Long-Term Effectiveness Of OnabotulinumtoxinA (Botox) And Anti CGRP In Migraine Prevention: A Systematic Review
Elizabeth Gaviria, Awab Hamid Eltayeb Hamid
F1000Research (2024) Vol. 13, pp. 665-665
Open Access | Times Cited: 1
Effectiveness and Tolerability of Anti-Calcitonin Gene-related Peptide Therapy for Migraines and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA
Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, et al.
(2024)
Open Access | Times Cited: 1
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine
Luigi Francesco Iannone, Davide Fattori, Martina Marangoni, et al.
CNS Drugs (2023) Vol. 37, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA
Lucas Hendrik Overeem, Raffaele Ornello, Maria Magdalena Pocora, et al.
CNS Drugs (2023) Vol. 37, Iss. 5, pp. 453-465
Open Access | Times Cited: 3

Scroll to top